Bristol-Myers Squibb Company

New York Stock Exchange
Back to all articles
Somewhat Bullish +45

Hudson Edge Investment Partners Inc. Has $8.42 Million Stock Position ...

AI-generated analysis

📉 Hudson Edge Investment Partners Inc. reduced its Bristol Myers Squibb stake by 17.7% in Q1, selling 29,888 shares to retain a position worth $8.42 million.

📈 Vanguard Group increased its BMY holdings by 1.4% in Q4, now owning 198,727,768 shares valued at approximately $10.7 billion.

📈 State Street Corp and Geode Capital Management also boosted their positions by 1.4% and 13.1% respectively during the fourth quarter.

🇳🇴 Norges Bank initiated a new stake in Bristol Myers Squibb valued at roughly $1.95 billion in Q4.

📈 AQR Capital Management significantly increased its position by 172.6%, acquiring an additional 16.3 million shares worth $1.39 billion.

💰 BMY declared a quarterly dividend of $0.63 per share with an ex-dividend date of July 2nd and a yield of 4.3%.

📊 The company trades at a market cap of $118.54 billion with a PE ratio of 16.31 and a beta of 0.23.

📈 Wall Street Zen upgraded BMY to a 'strong-buy' rating, while UBS reissued a 'buy' rating on the stock.

🎯 Analyst consensus remains 'Hold' with a price target of $61.31 based on ratings from eight buy, ten hold, and one sell analysts.

💊 Bristol Myers Squibb focuses its R&D and commercialization efforts on oncology, hematology, immunology, and cardiovascular diseases.

Bullish Signals
  • Major institutional investors including Vanguard, State Street, Geode Capital, Norges Bank, and AQR Capital Management all increased their stakes in the fourth quarter.
  • The company maintains a strong dividend yield of 4.3% with a payout ratio of 70.79%, providing consistent income to shareholders.
  • Wall Street Zen upgraded the stock from 'buy' to 'strong-buy', and UBS reissued a 'buy' rating, indicating analyst confidence.
  • Guggenheim reiterated a 'buy' rating and set a price target of $72.00, which is above the current trading price.
  • Institutional ownership remains high at 76.41%, suggesting broad support from large asset managers.
Risk Factors
  • Hudson Edge Investment Partners Inc. reduced its stake by 17.7% in Q1, signaling a decrease in interest from this specific investor.
  • The consensus analyst rating is 'Hold' with a price target of $61.31, which is below the current stock price of approximately $58.05 to $62.89 range depending on recent movement.
  • One analyst has assigned a 'Sell' rating to the company, contributing to a mixed sentiment profile.
Full Analysis
Hudson Edge Investment Partners Inc. reduced its stake in Bristol Myers Squibb (NYSE:BMY) by 17.7% during the first quarter, selling 29,888 shares to hold a remaining position of 138,879 shares valued at $8.42 million. This reduction brings BMY to 1.2% of Hudson Edge's total holdings, marking it as the firm's 12th largest position according to recent SEC 13F filings. Conversely, several major institutional investors increased their stakes in Bristol Myers Squibb during the fourth quarter. Vanguard Group boosted its position by 1.4% to own nearly 199 million shares worth over $10.7 billion, while State Street Corp and Geode Capital Management also added significant holdings. Norges Bank initiated a new stake valued at approximately $1.95 billion, and AQR Capital Management surged its position by 172.6%. The article details Bristol Myers Squibb's current financial metrics, noting a market capitalization of $118.54 billion and a dividend yield of 4.3%. The company recently declared a quarterly dividend of $0.63 per share payable on August 3rd for shareholders of record on July 2nd. Analyst consensus remains mixed with a 'Hold' rating and a price target of $61.31, though recent upgrades from Wall Street Zen and UBS suggest continued institutional interest. Bristol Myers Squibb operates as a global biopharmaceutical company headquartered in Princeton, New Jersey, focusing on oncology, hematology, immunology, and cardiovascular disease. The firm's portfolio emphasizes cancer and immune-mediated conditions through both small molecules and biologics. Institutional ownership stands at 76.41%, reflecting broad market confidence despite the recent reduction by Hudson Edge Investment Partners.